Literature DB >> 1733951

Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma.

M J Androlewicz1, J L Browning, C F Ware.   

Abstract

We characterized the membrane-associated form of lymphotoxin (surface LT) on the activated II-23.D7 T cell hybridoma. Antibodies to rLT precipitated both surface LT and a distinct 33-kDa glycoprotein (p33). Because p33 and surface LT were antigenically unrelated, their coprecipitation suggested a physical association of p33 and surface LT on the membrane. Pulse-chase analysis indicated that LT and p33 associate with each other early in the LT biosynthetic pathway, precluding the possibility that LT is secreted and bound to p33 or a surface receptor. Furthermore, no p33 was associated with the secreted form of LT. Isoelectric focusing of surface LT and p33 under nondenaturing and denaturing conditions confirmed that surface LT and p33 existed as a complex. Treatment of cells with a high concentration of salt or with acid indicated that surface LT is a peripheral membrane protein. Although secreted LT is a homologous trimer, protein cross-linking studies revealed that surface LT existed as a monomer associated with a dimer of p33. Together the results demonstrate a novel mechanism for stable membrane expression of LT by activated T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733951

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  LIGHT-related molecular network in the regulation of innate and adaptive immunity.

Authors:  Yanhui Xu; Koji Tamada; Lieping Chen
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 2.  Development of secondary lymphoid organs.

Authors:  Troy D Randall; Damian M Carragher; Javier Rangel-Moreno
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation.

Authors:  M Müller; H P Eugster; M Le Hir; A Shakhov; F Di Padova; C Maurer; V F Quesniaux; B Ryffel
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

Review 4.  Lymphotoxin and TNF: how it all began-a tribute to the travelers.

Authors:  Nancy H Ruddle
Journal:  Cytokine Growth Factor Rev       Date:  2014-02-12       Impact factor: 7.638

5.  Lymphotoxin-alpha contributes to lymphangiogenesis.

Authors:  Rawad H Mounzer; Oyvind S Svendsen; Peter Baluk; Cheryl M Bergman; Timothy P Padera; Helge Wiig; Rakesh K Jain; Donald M McDonald; Nancy H Ruddle
Journal:  Blood       Date:  2010-06-21       Impact factor: 22.113

6.  Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB.

Authors:  T L VanArsdale; S L VanArsdale; W R Force; B N Walter; G Mosialos; E Kieff; J C Reed; C F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Distinct roles of lymphotoxin alpha and the type I tumor necrosis factor (TNF) receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells.

Authors:  M Matsumoto; Y X Fu; H Molina; G Huang; J Kim; D A Thomas; M H Nahm; D D Chaplin
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

8.  Lymph node germinal centers form in the absence of follicular dendritic cell networks.

Authors:  P A Koni; R A Flavell
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

9.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

Review 10.  Lymphotoxin: from the physiology to the regeneration of the thymic function.

Authors:  Alexia Borelli; Magali Irla
Journal:  Cell Death Differ       Date:  2021-07-22       Impact factor: 12.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.